International Stem Cell CORP Operating Income Loss

• International Stem Cell CORP showed a decrease of -292.6% in Operating Income Loss from 2024 to 2025.
• This data is from International Stem Cell CORP's annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), International Stem Cell CORP's Operating Income Loss has grown by 97.4%.
• Historical annual values: Fiscal year 2025: -$267.0 thousand | Fiscal year 2024: -$68.0 thousand | Fiscal year 2023: -$663.0 thousand | Fiscal year 2022: -$183.0 thousand | Fiscal year 2021: -$1.92 million | Fiscal year 2020: -$2.82 million | Fiscal year 2019: -$5.73 million | Fiscal year 2018: -$3.47 million | Fiscal year 2017: -$4.94 million | Fiscal year 2016: -$4.85 million | Fiscal year 2015: -$4.56 million | Fiscal year 2014: -$8.68 million | Fiscal year 2013: -$7.55 million | Fiscal year 2012: -$9.82 million | Fiscal year 2011: -$11.36 million | Fiscal year 2010: -$10.46 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026